Martin Pruschy Selected Research

Medulloblastoma

5/2018	MAP4K4 controlled integrin β1 activation and c-Met endocytosis are associated with invasive behavior of medulloblastoma cells.
9/2017	Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response.
9/2011	The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells.
2/2011	c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients.
1/2009	RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin Pruschy Research Topics

Disease

55	Neoplasms (Cancer) 11/2023 - 02/2004
12	Hypoxia (Hypoxemia) 11/2023 - 06/2006
8	Carcinoma (Carcinomatosis) 01/2016 - 08/2005
5	Glioblastoma (Glioblastoma Multiforme) 01/2023 - 01/2012
5	Medulloblastoma 05/2018 - 01/2009
4	Glioma (Gliomas) 01/2023 - 01/2012
3	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 12/2017
3	Colonic Neoplasms (Colon Cancer) 01/2017 - 02/2005
3	Adenocarcinoma of Lung 04/2015 - 09/2011
2	Starvation 11/2023 - 12/2012
2	Hypersensitivity (Allergy) 04/2022 - 01/2014
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2021 - 02/2009
2	Residual Neoplasm 01/2020 - 02/2011
2	Squamous Cell Carcinoma of Head and Neck 12/2017 - 07/2007
1	Lymphopenia (Lymphocytopenia) 01/2022
1	Rhabdomyosarcoma 01/2021
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020
1	Malignant Mesothelioma 01/2018
1	Melanoma (Melanoma, Malignant) 01/2016
1	Sarcoma (Soft Tissue Sarcoma) 01/2016
1	Neoplasm Metastasis (Metastasis) 07/2014

Drug/Important Bio-Agent (IBA)

10	epothilone B (EPO906)IBA 04/2015 - 02/2005
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2021 - 02/2004
6	Phosphotransferases (Kinase)IBA 11/2023 - 08/2004
6	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2011 - 02/2004
5	Protons (Proton)IBA 04/2022 - 01/2014
5	Excipients (Suspending Agents)IBA 04/2015 - 06/2011
4	Biomarkers (Surrogate Marker)IBA 06/2021 - 06/2011
4	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 06/2006
4	TubulinIBA 01/2017 - 02/2005
4	vatalanib (PTK787)IBA 06/2011 - 02/2004
3	Metalloproteases (Metalloproteinases)IBA 01/2023 - 04/2013
3	Matrix Metalloproteinases (MMPs)IBA 12/2021 - 04/2013
3	Radiation-Sensitizing AgentsIBA 06/2021 - 02/2005
3	Oxygen (Dioxygen)IBA 01/2021 - 01/2012
3	DNA (Deoxyribonucleic Acid)IBA 03/2020 - 10/2011
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2017 - 02/2005
3	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2017 - 02/2005
3	taxaneIBA 01/2017 - 02/2005
3	Tyrosine Kinase InhibitorsIBA 06/2011 - 06/2006
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2008 - 06/2006
2	Small Interfering RNA (siRNA)IBA 11/2023 - 07/2014
2	IntegrinsIBA 01/2022 - 05/2018
2	Antineoplastic Agents (Antineoplastics)IBA 03/2020 - 01/2007
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2020 - 12/2017
2	Cetuximab (Erbitux)FDA Link 01/2020 - 01/2020
2	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 12/2012
2	Bevacizumab (Avastin)FDA Link 10/2017 - 04/2015
2	Messenger RNA (mRNA)IBA 09/2017 - 02/2011
2	ParaffinIBA 01/2016 - 02/2011
2	Formaldehyde (Formol)FDA Link 01/2016 - 02/2011
2	Conditioned Culture MediaIBA 07/2014 - 04/2013
2	Cytotoxins (Cytolysins)IBA 01/2012 - 01/2012
2	ErbB Receptors (EGF Receptor)IBA 08/2004 - 02/2004
2	midostaurinIBA 02/2004 - 02/2004
1	GoldIBA 10/2023
1	AmmoniaIBA 01/2023
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2023
1	tepotinibIBA 01/2023
1	STA 9090IBA 04/2022
1	minigastrinIBA 01/2022
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2022
1	Radioisotopes (Radionuclides)IBA 01/2022
1	Hemoglobins (Hemoglobin)IBA 01/2021
1	inositol trispyrophosphateIBA 01/2021
1	FenretinideIBA 01/2021
1	LigandsIBA 01/2018
1	Temozolomide (Temodar)FDA LinkGeneric 01/2018
1	IonsIBA 01/2018
1	Blocking AntibodiesIBA 01/2018
1	AntigensIBA 01/2018
1	TropomyosinIBA 09/2017
1	ProdrugsIBA 04/2017
1	TH 302IBA 04/2017
1	Oxidoreductases (Dehydrogenase)IBA 04/2017
1	BAL27862IBA 01/2017
1	lisavanbulinIBA 01/2017
1	Pemetrexed (MTA)FDA Link 01/2017
1	Epothilones (Epothilone)IBA 01/2017
1	N 30IBA 01/2016
1	von Willebrand FactorIBA 01/2016
1	Carbonic Anhydrase IXIBA 01/2016
1	Dexamethasone (Maxidex)FDA LinkGeneric 04/2015
1	AnaphylatoxinsIBA 04/2015
1	Complement System Proteins (Complement)IBA 04/2015
1	Angiogenesis InhibitorsIBA 04/2015
1	Everolimus FDA Link 04/2015
1	Protein-Lysine 6-Oxidase (Lysyl Oxidase)IBA 07/2014
1	Transforming Growth Factors (Transforming Growth Factor)IBA 07/2014
1	Hypoxia-Inducible Factor 1IBA 01/2014
1	BAY-84-7296IBA 01/2014

Therapy/Procedure

22	Radiotherapy 11/2023 - 02/2004
19	Therapeutics 01/2023 - 06/2004
7	Drug Therapy (Chemotherapy) 01/2021 - 08/2005
5	Chemoradiotherapy 01/2020 - 02/2004
2	Aftercare (After-Treatment) 04/2013 - 10/2008
1	Precision Medicine 03/2020
1	Proton Therapy 01/2020
1	Immunotherapy 01/2018
1	Craniospinal Irradiation 09/2017